PBX1 Genomic Pioneer Function Drives ERα Signaling Underlying Progression in Breast Cancer

English version České info

Altered transcriptional programs are a hallmark of diseases, yet how these are established is still ill-defined. PBX1 is a TALE homeodomain protein involved in the development of different types of cancers. The estrogen receptor alpha (ERα) is central to the development of two-thirds of all breast cancers. Here we demonstrate that PBX1 acts as a pioneer factor and is essential for the ERα-mediated transcriptional response driving aggressive tumors in breast cancer. Indeed, PBX1 expression correlates with ERα in primary breast tumors, and breast cancer cells depleted of PBX1 no longer proliferate following estrogen stimulation. Profiling PBX1 recruitment and chromatin accessibility across the genome of breast cancer cells through ChIP-seq and FAIRE-seq reveals that PBX1 is loaded and promotes chromatin openness at specific genomic locations through its capacity to read specific epigenetic signatures. Accordingly, PBX1 guides ERα recruitment to a specific subset of sites. Expression profiling studies demonstrate that PBX1 controls over 70% of the estrogen response. More importantly, the PBX1-dependent transcriptional program is associated with poor-outcome in breast cancer patients. Correspondingly, PBX1 expression alone can discriminate a priori the outcome in ERα-positive breast cancer patients. These features are markedly different from the previously characterized ERα-associated pioneer factor FoxA1. Indeed, PBX1 is the only pioneer factor identified to date that discriminates outcome such as metastasis in ERα-positive breast cancer patients. Together our results reveal that PBX1 is a novel pioneer factor defining aggressive ERα-positive breast tumors, as it guides ERα genomic activity to unique genomic regions promoting a transcriptional program favorable to breast cancer progression.

Vyšlo v časopise: PBX1 Genomic Pioneer Function Drives ERα Signaling Underlying Progression in Breast Cancer. PLoS Genet 7(11): e32767. doi:10.1371/journal.pgen.1002368
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1002368

Souhrn

Zdroje

1. BarreroMJBoueSIzpisua BelmonteJC 2010 Epigenetic mechanisms that regulate cell identity. Cell Stem Cell 7 565 570

2. MeissnerA 2010 Epigenetic modifications in pluripotent and differentiated cells. Nature Biotechnology 28 1079 1088

3. BernsteinBEMikkelsenTSXieXKamalMHuebertDJ 2006 A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125 315 326

4. MeissnerAMikkelsenTSGuHWernigMHannaJ 2008 Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454 766 770

5. MikkelsenTSHannaJZhangXKuMWernigM 2008 Dissecting direct reprogramming through integrative genomic analysis. Nature 454 49 55

6. LupienMEeckhouteJMeyerCAWangQZhangY 2008 FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132 958 970

7. CarrollJSMeyerCASongJLiWGeistlingerTR 2006 Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38 1289 1297

8. CarrollJSLiuXSBrodskyASLiWMeyerCA 2005 Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 33 43

9. HurtadoAHolmesKAGeistlingerTRHutchesonIRNicholsonRI 2008 Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456 663–U693

10. LinCYVegaVBThomsenJSZhangTKongSL 2007 Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 3 e87 doi:10.1371/journal.pgen.0030087

11. LiuYGaoHMarstrandTTStromAValenE 2008 The genome landscape of ER alpha- and ER beta-binding DNA regions. Proceedings of the National Academy of Sciences of the United States of America 105 2604 2609

12. HuaSKallenCBDharRBaqueroMTMasonCE 2008 Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 4 188

13. LaganiereJDebloisGLefebvreCBatailleARRobertF 2005 From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci U S A 102 11651 11656

14. EeckhouteJBricheIKurowskaMFormstecherPLaineB 2006 Hepatocyte nuclear factor 4 alpha ligand binding and F domains mediate interaction and transcriptional synergy with the pancreatic islet LIM HD transcription factor Isl1. Journal of Molecular Biology 364 567 581

15. MagnaniLEeckhouteJLupienM 2011 Pioneer factors: directing transcriptional regulators within the chromatin environment. Trends in Genetics In Press

16. CuestaIZaretKSSantistebanP 2007 The forkhead factor FoxE1 binds to the thyroperoxidase promoter during thyroid cell differentiation and modifies compacted chromatin structure. Mol Cell Biol 27 7302 7314

17. CirilloLALinFRCuestaIFriedmanDJarnikM 2002 Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol Cell 9 279 289

18. ZaretKSWattsJXuJWandziochESmaleST 2008 Pioneer factors, genetic competence, and inductive signaling: programming liver and pancreas progenitors from the endoderm. Cold Spring Harb Symp Quant Biol 73 119 126

19. SmaleST 2010 Pioneer factors in embryonic stem cells and differentiation. Curr Opin Genet Dev 20 519 526

20. WeigelDJackleH 1990 The fork head domain: a novel DNA binding motif of eukaryotic transcription factors? Cell 63 455 456

21. SpecchiaGLo CocoFVignettiMAvvisatiGFaziP 2001 Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol 19 4023 4028

22. SelleriLDepewMJJacobsYChandaSKTsangKY 2001 Requirement for Pbx1 in skeletal patterning and programming chondrocyte proliferation and differentiation. Development 128 3543 3557

23. KimSKSelleriLLeeJSZhangAYGuX 2002 Pbx1 inactivation disrupts pancreas development and in Ipf1-deficient mice promotes diabetes mellitus. Nat Genet 30 430 435

24. SchnabelCASelleriLClearyML 2003 Pbx1 is essential for adrenal development and urogenital differentiation. Genesis 37 123 130

25. SchnabelCAGodinREClearyML 2003 Pbx1 regulates nephrogenesis and ureteric branching in the developing kidney. Dev Biol 254 262 276

26. KampsMPMurreCSunXHBaltimoreD 1990 A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell 60 547 555

27. ParkJTShih IeMWangTL 2008 Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res 68 8852 8860

28. YehHYChengSWLinYCYehCYLinSF 2009 Identifying significant genetic regulatory networks in the prostate cancer from microarray data based on transcription factor analysis and conditional independency. BMC Med Genomics 2 70

29. LiuDBGuZDCaoXZLiuHLiJY 2005 Immunocytochemical detection of HoxD9 and Pbx1 homeodomain protein expression in Chinese esophageal squamous cell carcinomas. World J Gastroenterol 11 1562 1566

30. KikugawaTKinugasaYShiraishiKNanbaDNakashiroK 2006 PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation. Prostate 66 1092 1099

31. CrijnsAPde GraeffPGeertsDTen HoorKAHollemaH 2007 MEIS and PBX homeobox proteins in ovarian cancer. Eur J Cancer 43 2495 2505

32. MannRSChanSK 1996 Extra specificity from extradenticle: the partnership between HOX and PBX/EXD homeodomain proteins. Trends Genet 12 258 262

33. MoensCBSelleriL 2006 Hox cofactors in vertebrate development. Dev Biol 291 193 206

34. LaurentABihanROmilliFDeschampsSPellerinI 2008 PBX proteins: much more than Hox cofactors. Int J Dev Biol 52 9 20

35. LaurentABihanRDeschampsSGuerrierDDupeV 2007 Identification of a new type of PBX1 partner that contains zinc finger motifs and inhibits the binding of HOXA9-PBX1 to DNA. Mech Dev 124 364 376

36. BerkesCABergstromDAPennBHSeaverKJKnoepflerPS 2004 Pbx marks genes for activation by MyoD indicating a role for a homeodomain protein in establishing myogenic potential. Mol Cell 14 465 477

37. WangYYinLHillgartnerFB 2001 The homeodomain proteins PBX and MEIS1 are accessory factors that enhance thyroid hormone regulation of the malic enzyme gene in hepatocytes. J Biol Chem 276 23838 23848

38. SubramaniamNCairnsWOkretS 1998 Glucocorticoids repress transcription from a negative glucocorticoid response element recognized by two homeodomain-containing proteins, Pbx and Oct-1. J Biol Chem 273 23567 23574

39. EeckhouteJLupienMMeyerCAVerziMPShivdasaniRA 2009 Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers. Genome Res 19 372 380

40. NeveRMChinKFridlyandJYehJBaehnerFL 2006 A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10 515 527

41. WuCOrozcoCBoyerJLegliseMGoodaleJ 2009 BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol 10 R130

42. van de VijverMJHeYDvan't VeerLJDaiHHartAA 2002 A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 1999 2009

43. WangQLiWZhangYYuanXXuK 2009 Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138 245 256

44. HurtadoAHolmesKARoss-InnesCSSchmidtDCarrollJS 2011 FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature Genetics 43 27–U42

45. SchmidtDSchwaliePCRoss-InnesCSHurtadoABrownGD 2010 A CTCF-independent role for cohesin in tissue-specific transcription. Genome Res 20 578 588

46. WelborenWJvan DrielMAJanssen-MegensEMvan HeeringenSJSweepFCGJ 2009 ChIP-Seq of ER alpha and RNA polymerase II defines genes differentially responding to ligands. Embo Journal 28 1418 1428

47. CicatielloLMutarelliMGroberOMParisOFerraroL 2010 Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. Am J Pathol 176 2113 2130

48. TsaiWWWangZYiuTTAkdemirKCXiaW 2010 TRIM24 links a non-canonical histone signature to breast cancer. Nature 468 927 932

49. HuMYuJTaylorJMChinnaiyanAMQinZS 2010 On the detection and refinement of transcription factor binding sites using ChIP-Seq data. Nucleic Acids Res 38 2154 2167

50. JosephROrlovYLHussMSunWKongSL 2010 Integrative model of genomic factors for determining binding site selection by estrogen receptor-alpha. Mol Syst Biol 6 456

51. HuaSJKittlerRWhiteKP 2009 Genomic Antagonism between Retinoic Acid and Estrogen Signaling in Breast Cancer. Cell 137 1259 1271

52. RichardsonALWangZGCDe NicoloALuXBrownM 2006 X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9 121 132

53. ButtAJMcNeilCMMusgroveEASutherlandRL 2005 Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12 Suppl 1 S47 59

54. DuanRPorterWSafeS 1998 Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology 139 1981 1990

55. InoueAOmotoYYamaguchiYKiyamaRHayashiSI 2004 Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J Mol Endocrinol 32 649 661

56. StackGKumarVGreenSPonglikitmongkolMBerryM 1988 Structure and function of the pS2 gene and estrogen receptor in human breast cancer cells. Cancer Treat Res 40 185 206

57. GiresiPGKimJMcDaniellRMIyerVRLiebJD 2007 FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. Genome Res 17 877 885

58. BrykczynskaUHisanoMErkekSRamosLOakeleyEJ 2010 Repressive and active histone methylation mark distinct promoters in human and mouse spermatozoa. Nature Structural & Molecular Biology 17 679 U647

59. BhandareRSchugJLe LayJFoxASmirnovaO 2010 Genome-wide analysis of histone modifications in human pancreatic islets. Genome Research 20 428 433

60. HeintzmanNDHonGCHawkinsRDKheradpourPStarkA 2009 Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 459 108 112

61. OrfordKKharchenkoPLaiWDaoMCWorhunskyDJ 2008 Differential H3K4 methylation identifies developmentally poised hematopoietic genes. Developmental Cell 14 798 809

62. SerandourAAAvnerSPercevaultFDemayFBizotM 2011 Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Res 21 555 565

63. SorlieTPerouCMTibshiraniRAasTGeislerS 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98 10869 10874

64. PayneSJBowenRLJonesJLWellsCA 2008 Predictive markers in breast cancer–the present. Histopathology 52 82 90

65. BadveSTurbinDThoratMAMorimiyaANielsenTO 2007 FOXA1 expression in breast cancer–correlation with luminal subtype A and survival. Clin Cancer Res 13 4415 4421

66. ThoratMAMarchioCMorimiyaASavageKNakshatriH 2008 Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol 61 327 332

67. HabashyHOPoweDGRakhaEABallGPaishC 2008 Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 44 1541 1551

68. GyorffyBLanczkyAEklundACDenkertCBudcziesJ 2010 An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123 725 731

69. ChoeSKLuPNakamuraMLeeJSagerstromCG 2009 Meis cofactors control HDAC and CBP accessibility at Hox-regulated promoters during zebrafish embryogenesis. Dev Cell 17 561 567

70. HoffmanBGRobertsonGZavagliaBBeachMCullumR 2010 Locus co-occupancy, nucleosome positioning, and H3K4me1 regulate the functionality of FOXA2-, HNF4A-, and PDX1-bound loci in islets and liver. Genome Research 20 1037 1051

71. JacobsYSchnabelCAClearyML 1999 Trimeric association of hox and TALE homeodomain proteins mediates Hoxb2 hindbrain enhancer activity. Molecular and Cellular Biology 19 5134 5142

72. ChangCPShenWFRozenfeldSLawrenceHJLargmanC 1995 Pbx Proteins Display Hexapeptide-Dependent Cooperative DNA-Binding with a Subset of Hox Proteins. Genes & Development 9 663 674

73. BurdaPLasloPStopkaT 2010 The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis. Leukemia 24 1249 1257

74. KorkolaJEBlaveriEDeVriesSMooreDH2ndHwangES 2007 Identification of a robust gene signature that predicts breast cancer outcome in independent data sets. BMC Cancer 7 61

75. KaoKJChangKMHsuHCHuangAT 2011 Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11 143

76. AllisonKHKandalaftPLSitlaniCMDintzisSMGownAM 2011 Routine pathologic parameters can predict Oncotype DX(TM) recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat

77. ToiMIwataHYamanakaTMasudaNOhnoS 2010 Clinical Significance of the 21-Gene Signature (Oncotype DX) in Hormone Receptor-Positive Early Stage Primary Breast Cancer in the Japanese Population. Cancer 116 3112 3118

78. SwantonCDownwardJ 2008 Unraveling the complexity of endocrine resistance in breast cancer by functional genomics. Cancer Cell 13 83 85

79. BlankenbergDVon KusterGCoraorNAnandaGLazarusR 2010 Galaxy: a web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol Chapter 19: Unit 19 10 11 21

80. BirneyEStamatoyannopoulosJADuttaAGuigoRGingerasTR 2007 Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447 799 816

81. WangKSenguptaSMagnaniLWilsonCAHenryRW 2010 Brg1 is required for Cdx2-mediated repression of Oct4 expression in mouse blastocysts. PLoS ONE 5 e10622 doi:10.1371/journal.pone.0010622

82. LupienMMeyerCABaileySTEeckhouteJCookJ 2010 Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 24 2219 2227

83. Ross-InnesCSStarkRHolmesKASchmidtDSpyrouC 2010 Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev 24 171 182

84. ZhangYLiuTMeyerCAEeckhouteJJohnsonDS 2008 Model-based analysis of ChIP-Seq (MACS). Genome Biol 9 R137

85. LoiSHaibe-KainsBDesmedtCLallemandFTuttAM 2007 Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25 1239 1246

86. van 't VeerLJDaiHvan de VijverMJHeYDHartAA 2002 Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 530 536

87. DesmedtCPietteFLoiSWangYLallemandF 2007 Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13 3207 3214

88. LoiSHaibe-KainsBDesmedtCWirapatiPLallemandF 2008 Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9 239

89. WangYKlijnJGZhangYSieuwertsAMLookMP 2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 671 679

90. SotiriouCNeoSYMcShaneLMKornELLongPM 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100 10393 10398

91. MinnAJGuptaGPSiegelPMBosPDShuW 2005 Genes that mediate breast cancer metastasis to lung. Nature 436 518 524

92. PawitanYBjohleJAmlerLBorgALEgyhaziS 2005 Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Research 7 R953 R964

93. BittnerM 2005 Expression Project for Oncology - Breast Samples not published

94. IvshinaAVGeorgeJSenkoOMowBPuttiTC 2006 Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Research 66 10292 10301

95. SchmidtMBohmDvon TorneCSteinerEPuhlA 2008 The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Research 68 5405 5413

96. ZhaoHJLangerodAJiYNowelsKWNeslandJM 2004 Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Molecular Biology of the Cell 15 2523 2536

97. LuXSLuXWangZCGIglehartJDZhangXG 2008 Predicting features of breast cancer with gene expression patterns. Breast Cancer Research and Treatment 108 191 201

98. YuKGanesanKMillerLDTanP 2006 A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor - Positive tumors. Clinical Cancer Research 12 3288 3296

99. HessKRAndersonKSymmansWFValeroVIbrahimN 2006 Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24 4236 4244

100. KreikeBHalfwerkHKristelPGlasAPeterseH 2006 Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res 12 5705 5712

101. SorlieTTibshiraniRParkerJHastieTMarronJS 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 100 8418 8423

102. PerouCMSorlieTEisenMBvan de RijnMJeffreySS 2000 Molecular portraits of human breast tumours. Nature 406 747 752

103. JulkaPKChackoRTNagSParshadRNairA 2008 A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. British Journal of Cancer 98 1327 1335